Skip to main content

Fiscal Wizard · Single-issue tearsheet

VRDN / Jun 21, 2026 Run #7287

VRDN

Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.

Composite verdict

F 12.5 / 100
Bearish setup · Trend Following 8 drivers · 6 gates blocking
  • Chaikin Money Flow
  • Vortex Signal
  • Fibonacci Retracement
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 403rd of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: range
Bull 0%Evidence: High · 15 signals100% Bear
Momentum Bearish 4Mean-reversion Neutral 48

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes from

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Weak

24.8 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Cash Conversion Cycle 100
Free Cash Flow Yield 0
Days Sales Outstanding 100
FCF Margin 0
Inventory Turnover 100
EBITDA Margin 0

Technicals Bearish

0.3 / 100

Bearish setup leads (Chaikin Money Flow, Vortex Signal, Fibonacci Retracement); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Chaikin Money Flow 7
Vortex Signal 14
Fibonacci Retracement 18

Risk Gates

6 blocking 4 caution

6 guards active, 25 signals gated.

Interest Coverage Blocking

Weak interest coverage blocks bullish signals — debt-service risk.

Piotroski F-Score Blocking

Bottom-band Piotroski F blocks bullish signals — fundamental-quality risk.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for VRDN.